Metabolic
5-Amino-1MQ
R350
Metabolic
Tesamorelin (10mg)
An advanced peptide option for individuals prioritising visceral fat reduction, metabolic health, and long-term body composition optimisation.
R1 500
1
- Includes enough bacteriostatic water to reconstitute this vial, at no extra cost.
- Courier delivery across South Africa, 2 to 5 business days.
- Dispatched within 1 to 2 business days with tracking.
- Supplied for research and educational purposes only.
- No change-of-mind returns. Anything damaged, faulty or incorrect is replaced or refunded.
Recommended by the Stack Finder in
What the research says
GHRH analogue
Tesamorelin
The only growth-hormone-axis peptide with an approved indication for reducing visceral (deep abdominal) fat.
- How it works
- Mimics growth-hormone-releasing hormone, increasing the body's own pulsatile growth hormone output, which preferentially mobilises visceral fat.
- Research status
- Approved medicine (Egrifta) for HIV-associated abdominal fat, backed by phase 3 randomised trials.
- Timeline in the research
- Visceral fat changes are measurable at 3 months and continue to 6 months.
- Cautions
- Raises IGF-1; not appropriate with active cancer or a recent cancer history.
- Can impair glucose tolerance, so blood sugar should be monitored, especially with diabetes.
- Injection-site reactions and fluid retention are the most common side effects.
Key studies
Visceral fat fell by 15.2% over 26 weeks versus a 5% increase on placebo, with no change in subcutaneous fat.
Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370. doi:10.1056/NEJMoa072375
Pooled analysis of two phase 3 trials confirmed the visceral fat reduction, with IGF-1 increases and glucose changes as the main safety signals.
Falutz J et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291-4304. doi:10.1210/jc.2010-0490
Reduced visceral fat and liver fat over 12 months in adults with abdominal fat accumulation.
Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312:380-389. doi:10.1001/jama.2014.8334
About this product
An advanced peptide option for individuals prioritising visceral fat reduction, metabolic health, and long-term body composition optimisation.
Tesamorelin 10mg is a synthetic growth hormone–releasing peptide designed to support the reduction of visceral fat while promoting healthier metabolic function. It is particularly suited for individuals focused on improving abdominal fat distribution, metabolic efficiency, and long-term health rather than short-term weight loss alone.
What Is Tesamorelin?
Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue that stimulates the body’s natural production of growth hormone. By enhancing endogenous growth hormone signalling, Tesamorelin supports metabolic processes involved in fat utilisation, tissue health, and body composition.
Unlike direct hormone replacement, Tesamorelin works by encouraging the body to produce its own growth hormone, making it a more physiologically aligned option for long-term metabolic support.
Its targeted action has made it particularly relevant in the context of visceral fat — the deeper, metabolically active fat linked to insulin resistance and cardiometabolic risk.
Visceral Fat & Metabolic Health Support
Research suggests that Tesamorelin may play a role in reducing visceral adipose tissue, especially in the abdominal region. Visceral fat is closely associated with metabolic dysfunction, inflammation, and increased long-term health risk.
By supporting healthier growth hormone signalling, Tesamorelin may help shift fat distribution away from high-risk visceral stores while supporting improved metabolic efficiency.
This makes Tesamorelin a longevity-aligned option for individuals prioritising organ health, metabolic balance, and sustainable body composition improvement.
Key Benefits
• Supports reduction of visceral (abdominal) fat
• Promotes healthy growth hormone signalling
• Aids metabolic efficiency and body composition
• Supports insulin sensitivity and lipid metabolism
• Longevity-aligned approach to fat distribution
Who Tesamorelin Is Ideal For
Tesamorelin is well suited for individuals who:
• Carry stubborn abdominal or visceral fat
• Are concerned about metabolic or cardiometabolic risk
• Want to improve fat distribution rather than just scale weight
• Prefer a physiologically aligned, long-term strategy
• Are focused on metabolic health and longevity
This peptide is designed for individuals thinking years ahead — not chasing quick fixes.
Product Details
• Peptide: Tesamorelin
• Amount: 10mg per vial
• Format: Lyophilised (freeze-dried) powder
• Category: Metabolic Health | Body Composition | Longevity
• Storage: Refrigerate after reconstitution
What You’ll Also Need
This peptide requires reconstitution prior to use. Sterile reconstitution water is included with your order.
• Reconstitution Syringe
• Insulin Syringes
• Alcohol Swabs
These essentials can be added below for convenience.
FAQ
Q: What type of fat is Tesamorelin commonly associated with?
A: It is often discussed in relation to visceral fat and abdominal fat distribution.
Q: How is Tesamorelin different from standard fat-loss peptides?
A: It is commonly linked to growth hormone signalling pathways rather than direct fat metabolism or appetite suppression.
Q: What makes Tesamorelin unique in body composition support?
A: It is typically positioned around body recomposition and metabolic signalling rather than simple weight loss.
Important Note
This product is intended for research and educational purposes only.
Always consult a qualified healthcare professional before beginning any new peptide protocol.
